Further characterization of the ppGalNAcT family: To date, 16 human ppGalNAcT isoforms have been described in the literature. Jaya Raman has conducted an extensive search of human and mouse nucleotide sequence databases that revealed the existence of an additional 4 human isoforms which she is characterizing (together with other members of the lab) with respect to expression pattern, and relatedness to known family members by sequence analysis and enzymatic activity. In a manuscript that is being revised, we will assign unique names to each of these novel isoforms and propose names for several previously described mammalian ppGalNAcTs to eliminate confusion present within the nomenclature of current sequence databases and the ppGalNAcT literature. Molecular mechanisms of ppGalNAcT catalysis: Some members of the ppGalNAcT family demonstrate preference for substrates that are already decorated with GalNAc (i.e. glycopeptides). In collaboration with Tom Gerkin Tim Fritz and Jaya Raman emplyed a series of random peptide and glycopeptide substrates to evaluate the substrate specficities of ppGalNAcT-10 (which prefers glycopeptides) and ppGalNAcT-1 and T-2 (which prefer peptides). ppGalNAc T10 exhibited strong preference for Ser/Thr-O-GalNAc at the +1, C-terminal position relative to a Ser/Thr acceptor site and no preferences for specific amino acids. Biological consequences of ablating expression/activity of ppGalNAcTs: In collaboration with Stasia Anderson, Daryl Despres and M Starost from NIH, Yu Guan has studied the cardiac phenotypes resulting from the deletion of ppGalNAcT-1. She found that the heart/body weight ratio was increased in 4-month-old KO animals compared to heterozygotes and wild-type littermate controls. Histological analysis revealed right or left ventricle hypertrophy, enlarged cardiomyocytes, increased interstitial fibrosis, and mitochondria swelling and dissolution in knockout animals. Further analysis revealed that the heart valves are markedly enlarged in the affected hearts. Yu is analyzing the underlying molecular cause(s) for this phenotype. We continue to collaborate with Suzanne Walker (Harvard) to identify small molecule inhibitors of ppGalNAcTs. Yu Guan is performing the biological assays on cell lines with candidate inhibitors. We have begun collaboration with Jesse Mager to evaluate role of ppGalNAcT-3 in sperm development and maturation.
|Gerken, Thomas A; Jamison, Oliver; Perrine, Cynthia L et al. (2011) Emerging paradigms for the initiation of mucin-type protein O-glycosylation by the polypeptide GalNAc transferase family of glycosyltransferases. J Biol Chem 286:14493-507|
|Tabak, Lawrence A (2010) The role of mucin-type O-glycans in eukaryotic development. Semin Cell Dev Biol 21:616-21|
|Miwa, Hazuki E; Gerken, Thomas A; Jamison, Oliver et al. (2010) Isoform-specific O-glycosylation of osteopontin and bone sialoprotein by polypeptide N-acetylgalactosaminyltransferase-1. J Biol Chem 285:1208-19|
|Perrine, Cynthia L; Ganguli, Anjali; Wu, Peng et al. (2009) Glycopeptide-preferring polypeptide GalNAc transferase 10 (ppGalNAc T10), involved in mucin-type O-glycosylation, has a unique GalNAc-O-Ser/Thr-binding site in its catalytic domain not found in ppGalNAc T1 or T2. J Biol Chem 284:20387-97|
|Tian, E; Ten Hagen, Kelly G; Shum, Lillian et al. (2008) An inhibitor of O-glycosylation induces apoptosis in NIH3T3 cells and developing mouse embryonic mandibular tissues. J Biol Chem 283:4460|
|Raman, Jayalakshmi; Fritz, Timothy A; Gerken, Thomas A et al. (2008) The catalytic and lectin domains of UDP-GalNAc:polypeptide alpha-N-Acetylgalactosaminyltransferase function in concert to direct glycosylation site selection. J Biol Chem 283:22942-51|